KRTX News and Press, Karuna Therapeutics Inc. From 03/20/23

Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a side effect profile substantially consistent with previous trials of ...

Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a side effect profile substantially consistent with previous trials of Ka...

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...

2023-03-10 21:26:19 ET Several smaller pharma and biotech companies have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). The biotech was the biggest exposure disclosed so far is Sangamo Therapeutics ( NASDAQ: SGMO ), with $34.4M in ...

2023-03-08 08:46:08 ET Cantor Fitzgerald launched its coverage on Karuna Therapeutics ( NASDAQ: KRTX ) with a Neutral rating and a $214 price target, citing its lead product candidate KarXT, an oral therapy which modulates muscarinic receptors in the central nervous system and o...

Summary As Covid-19 problems settle into recurring problems, other biotechnology targets become more active treatment subjects. The psychiatric and neurological conditions of Karuna’s focus are receiving increased investing attention. “Likely” is the keyword in unce...

Karuna Therapeutics press release ( NASDAQ: KRTX ): Q4 GAAP EPS of -$2.22 beats by $0.06 . Revenue of $5.28M (-85.7% Y/Y). $1.1 billion in cash is expected to fund operations through the end of 2025 For further details see: Karuna Therapeutics GAAP EPS of -$2.22 ...

Topline data from Phase 3 EMERGENT-3 trial anticipated in the first quarter of 2023 On track to submit New Drug Application (NDA) for KarXT in schizophrenia to the U.S. Food & Drug Administration (FDA) in mid-2023 Announced exclusive global license agreement for investigationa...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the SVB Securities Global Biopharma Conference...

Karuna Therapeutics ( NASDAQ: KRTX ) signed an agreement to get global development, manufacturing, and sale rights to Goldfinch Bio's investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates, including lead drug GFB-887. Karuna plans to evaluate thes...